Pharma companies stress need for personalised cancer treatment

Greater use of biomarkers to steer therapy should be an EU priority, trade body says

Drug companies have said personalised cancer treatment should be a major part of the EU’s strategy to tackle the disease, along with national monitoring, data-informed care and faster regulatory approval.

The European Federation of Pharmaceutical Industries and Associations, an umbrella body, was responding on 2 September to a draft European Parliament report from a special committee on cancer, designed to flesh out the EU’s anti-cancer strategy.